Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 15/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22985032 | 0.97 | AR (0.42) | ARPGRNR3C1PDE3BPDE3A | |
| SCHEMBL22985540 | 0.95 | AR (0.40) | ARPGRRORC | |
| SCHEMBL22985675 | 0.95 | AR (0.40) | ARPGRRORC | |
| SCHEMBL22985671 | 0.95 | AR (0.40) | ARPGRRORC | |
| SCHEMBL22985672 | 0.94 | AR (0.38) | ARPGR | |
| SCHEMBL22985543 | 0.93 | AR (0.47) | ARPGRRORC | |
| SCHEMBL22985031 | 0.93 | AR (0.37) | ARPGRRORC | |
| SCHEMBL22985035 | 0.93 | AR (0.37) | ARPGRRORC | |
| SCHEMBL22985396 | 0.93 | AR (0.37) | ARPGRRORC | |
| SCHEMBL22985028 | 0.93 | AR (0.36) | ARPGRNR3C1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919880-B2 | Organic molecules, in particular for use in optoelectronic devices | CYNORA GMBH (DE) | 2021-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919880-B2 | Organic molecules, in particular for use in optoelectronic devices | OCIAD1, OCIAD2, POU2F1 | AR 3541/4885PGR 3779/4885NR3C1 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.